Reserved area

Credentials and contents in the EryDel “RESERVED AREA” are strictly confidential and the access is authorized only for the medical staff operating the EDS in the ATTeST study. The Content of the “RESERVED AREA” should not be copied, distributed or reproduced in whole or in part, nor distributed to any third party if not for the  training purpose of authorized EDS Operators. The Content of the “RESERVED AREA” is only for medically trained staff.

I Agree

Board of Directors 

Luca Benatti / Chief Executive Officer

Dr Luca Benatti is the Chief Executive Officer since June 2012. He has over 25 year experience in Pharma and Biotech. He was Co-founder and CEO of Newron Pharmaceuticals (NWRN, Swiss Stock Exchange). Under his guidance, Newron developed a pipeline of innovative therapies including Xadago, approved wordwide for the  treatment of Parkinson's disease. Luca graduated and performed his post-doctoral training at Milano Genetics Institute. He is an independent Board member at Intercept Pharmaceuticals (ICPT, Nasdaq),  Newron Pharmaceuticals,  Chairman of the Italian Angels for Biotech, Member of the Strategic Advisory Board of Zambon, Member of the Board of Assobiotec, Member of the Jury of the European Biotechnica Award and of the Open Accelerator Award.  He has authored several scientific publications and holds numerous patents.

Mauro Magnani / Chief Scientific Officer / Co-Founder

Prof. Mauro Magnani is the Company co-founder and Chief Scientific Officer and Director since 2007. He is Professor of Biochemistry and Director of the Centre of Biotechnology at the University of Urbino, Italy.
Prof. Magnani is an international leader in the development of drug delivery technologies using red blood cells. During his academic career he has been: Visiting Researcher, Dept. Biochemistry, Univ. Birmingham, 1980; Visiting Prof. Dept. Biology, Haifa, Israel. Since 1986 he is Full Professor of Biochemistry ; Dean, Faculty of Sciences University of Urbino 1995-2001; Director Interuniversity Consortium for Biotechnology (CIB) 1998-2004; Vice Rector of the University of Urbino 2001-2009. He is also a "Technical Director" nominated by the "Agenzia Italiana del Farmaco, AIFA" with n. AIDT-19/2005. Co-founder of various start-up companies, and author of more than 400 papers published in international refereed scientific journals and inventor of numerous patents; Co-editor of three books and reviewer for over 30 international Journals.

Lorenzo Tallarigo / Chairman

 Lorenzo Tallarigo , Chairman since 2013. He joined Genextra in may 2009 as Chief Executive Officer.
Previously Dr. Tallarigo worked at Eli Lilly since 1985 where he held various positions in areas of clinical research, pharmaceutical product management and marketing and general management, most recently as its president of international operations.Dr. Tallarigo is a member of the board of trustees for the University of Indianapolis and is a member of the international committee of the Indiana University Foundation.
Dr. Tallarigo received a doctor of medicine degree from the University of Pisa (Italy).

Paolo Fundarò / Director

Paolo Fundaro’, Director since 2013. He has been Genextra’s Chief Financial Officer since its inception in 2004, Member of the Board of Intercept Pharmaceuticals, Inc. since 2006 and Managing Director of the other Genextra’s portfolio companies.  Before joining Genextra, Paolo  was director of finance and strategic planning for the Fastweb Group from 2000 to 2004. Previously, he worked for investment banks in London, including Salomon Smith Barney (now Citigroup) and Donaldson Lufkin & Jenrette (now Credit Suisse). He has a degree in Business Management from the Bocconi University in Milan.

Federica Draghi/ Director

 Federica Draghi, Director since 2013. Federica is Director of Business Development at Genextra where, since she joined in 2006, she has been overviewing a number of activities ranging from evaluation of new investing opportunities to partnering, licensing as well as strategic development of Genextra's subsidiary companies. Before joining Genextra, Federica was at Windham Venture Partners, a NYC based life sciences technology commercialization firm, and prior to that with Science and Technology Ventures, Columbia University's tech transfer office. Previously, she was a postdoc at the MRC in Cambridge (UK) and has been published in several journals. Federica holds an MBA from Columbia University and a PhD in Biochemistry from La Sapienza, University of Rome.

Claudio Rumazza/ Director

Claudio Rumazza, Director since 2013. Claudio is a Partner at Innogest, the leading Italian Venture Capital firm. Before joining Innogest, Claudio held several roles at Prima Industrie SpA where most recently he was CFO of Finn-Power Group and previously head of financial planning and business development for Prima Group. Previously he worked for Deloitte Financial Advisory Services SpA where he advised primary private equity funds and strategic buyers on numerous M&A transactions. Claudio received a Master’s Degree in Economics from the University of Turin.

Where We Are